Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon
The entrance to the AHA expo and technology floor. #AHA22

American Heart Association announces late-breaking research for Scientific Sessions 2024

The three-day conference begins Saturday, Nov. 16, in Chicago. Topics will include AI, heart failure, patient management and much more. 

Impella ECP heart pump insertion Abiomed Johnson & Johnson MedTech

Impella ECP confirmed to be safe for high-risk PCI—is FDA approval next?

The Impella ECP heart pump, which measures at just 3 mm in length, was linked to positive safety data in a new study presented at TCT 2024.

CVRx banner

New Category I CPT codes announced for treating heart failure with implantable Barostim device

Baroreflex activation therapy with the Barostim device from CVRx has received new CPT codes from the American Medical Association. The codes go into effect in January 2026.

Advanced device-based therapies are associated with significant benefits for heart failure patients and should be used alongside traditional pharmaceutical treatments, according to a new scientific statement from the Heart Failure Society of America (HFSA). The statement, published in full in the Journal of Cardiac Failure, examines a number of new-look medical devices that have emerged in recent years as additional ways to treat heart failure.

Cardiologists make case for increasing use of device-based therapies for heart failure

Device-based therapies can provide considerable value for heart failure patients when used alongside traditional pharmaceutical treatments. A new HFSA scientific statement outlines the benefits of these devices, urging care teams to implement them into daily practice. 

Thumbnail

Obesity-related deaths on the rise in US—but there is good news for cardiologists

Deaths related to obesity have skyrocketed in the United States, especially among men. However, researchers identified positive progress when it came to the mortality rates for CVD, ischemic heart disease and heart failure/cardiomyopathy.

V-Wave has gained considerable attention or its Ventura Interatrial Shunt System, a small implantable device designed to reduce pressure on the left atrium and the lungs in patients with heart failure with reduced ejection fraction (HFrEF). The Ventura device includes a nitinol hourglass-shaped frame that anchors to the patient’s fossa ovalis in a way that prevents migration or embolization. It is implanted via an interventional procedure with fluoroscopy and echocardiography guidance.

Johnson & Johnson completes V-Wave acquisition

While the initial purchase price was $600 million, the final amount could reach approximately $1.7 billion if certain milestones are met. V-Wave's Ventura Interatrial Shunt System for HFrEF has gained considerable interest in recent years, and Johnson & Johnson was an early investor in the technology back in 2016.

Monitoring acute heart patients at home linked to considerable cost savings

The new report could go on to help guide decisions made by CMS and hospital leadership teams for years to come.

Thumbnail

Following heart failure guidelines could save 1.2 million lives per year

Millions of heart failure patients who qualify for standard medical therapies do not receive treatment due to poor health literacy, limited access to care and medication costs.

Displaying 1 - 8 of 964

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup